News

A team of cancer researchers led by scientists at UC San Francisco and Memorial Sloan Kettering Cancer Center demonstrated in human cells and mouse models that a first-of-its-kind hybrid drug can outsmart drug-resistant cancers. The new drug physically yokes together two existing drugs against a

Five UC San Francisco faculty members have been elected to the American Society for Clinical Investigation (ASCI) after a highly competitive nomination process. The ASCI, which is one of the oldest medical honor societies in the United States, received 160 membership nominations for 2016 and

Time magazine has named internationally renowned breast cancer oncologist Laura Esserman, MD, MBA, to the 2016 TIME 100, the magazine’s annual list of the 100 most influential people in the world. Esserman has been at the forefront of efforts to change the delivery of breast cancer services as well

As more people get their hands on their own genetic data each day, many face an increasingly common question: What do you do if you carry a genetic risk factor for cancer? While knowing genetic mutations can help clinicians decide on treatment options for patients, the data raises more questions

NEW ORLEANS — Stand Up To Cancer (SU2C) announced Monday that it is awarding 10 grants of $750,000 each to early-career scientists to support innovative, high-risk, high-reward projects in cancer research. The announcement was made at the 2016 Annual Meeting of the American Association for Cancer

UC San Francisco researchers have discovered that the chances of survival for patients with pancreatic adenocarcinoma (PDAC) — the most common type of pancreatic cancer — may depend in part on how tense their tumors are. The researchers provide the first evidence linking tumor aggressiveness and

UC San Francisco oncologist Lawrence Fong, MD, personifies the tremendous excitement among cancer physicians over the growing potential of new immunotherapies. He smiles often as he explains how the body’s own immune system – long thought to be an ineffective slacker when it comes to combatting